|
|
|
International Clinical Trials
|
Of late, ‘partnerships’ has been the buzz word of the day at conferences
and in boardrooms. Strategic partnerships between large service
providers and big pharmaceutical companies make sense, but how can the
smaller players out there reap the rewards from a close partnership if a
formal strategic option is not appropriate?
Specialist CROs and service providers to small and medium sized
biotechnology and pharmaceutical companies are used to forging
partnerships with clients, and realising the benefits that
pharmaceutical and biotechnology companies can gain from their service
providers, beyond the traditional services that are provided – extra
benefits that are not immediately obvious. So what else can be done to
work together beyond the traditional relationship? Before answering the
question, it is important to share some of the feedback we get on a
regular basis from our own clients.
The biggest problem is that sponsors are seen as customers, particularly
within the bigger service providers. This is fully understandable when a
company is dealing with a multinational service provider who has set
procedures and project guidelines. The relationship can be very
transactional, and everyone is working to tight budgets. What sponsors
want is to be considered part of the team. They want someone from the
service provider to work with them and to be considered one of their
own. They want passion, and people who are working in partnership
towards a successful result; they want the procedures to work for them,
not against them.
How is it possible to achieve this utopian relationship between the
sponsor and the service provider? Simple; it’s all about expectations.
People don’t care how much is offered to them; they care about whether
their expectations have been exceeded. To achieve a true partnership the
secret is simple – service providers need to give them more than they
expected.
As a service provider, in our rush to get picked, get shortlisted or
build revenue, the instinct is to promise more for less. Perhaps it pays
to promise less for more instead, to radically change expectations and
to reset what it means to deliver on the promise of partnership. To
understand the opportunity in more detail, see Figure 1.
The service provider/sponsor relationship is a package deal. Sponsors
have a study or set of studies that they want to run, they package it up
and contract some of this work out. The sponsor will also contract out
the analysis plan, the tables and figures, and statistical report or
CSR. Typically, this is everything on the right side (cost conscious
side) of the value molecule.
The service provider will bid, win and complete this work. They’ll gain a
huge amount of experience and knowledge while doing it and then they
pass it back. And that’s the end of the story. Everything that’s been
done on Phase 1, Phase 2 and Phase 3 studies, every investment the
sponsor has given, in both time and fees to the provider to get them up
to speed, is potentially lost. They’ve lost all that experience. Why
does this happen? It all comes down to the ‘Law of stuck’.
Here’s a good example of the Law of stuck. Is there a single person
alive who is capable of boarding an aeroplane who then has become stuck
in their seat because they didn’t know how to unbuckle the seatbelt?
There is 100 per cent seatbelt understanding among air passengers today,
so why do flight attendants still demonstrate how the seat belt works
on every flight? Like so many policies in our organisations today,
inertia has set in. The service provider delivers what they are asked to
deliver as efficiently and as effortlessly as possible. They then hand
back the data and move on. No value, no partnership and a truly
forgettable transactional relationship.
I challenge the talented professionals out there within service
providers to look up and see where they can exceed expectations with
clients throughout the whole value molecule. They should then challenge
the internal hierarchy to deliver those solutions and expertise to the
sponsor.
Fresh Thinking
One approach to getting unstuck is the clean sheet of paper. Move your
team to the coffee shop across the street, open a new location,
completely rewrite your services handbook, throw out the standard terms
and conditions and give your team the room to invent. What value can you
add on the left side of the value molecule?
Sponsors should be ensuring that the wealth of experience and
understanding of data gained from completing that traditional right hand
side of the value molecule remains a valuable asset to the business
post registration.
Service providers, depending on the size of the business, might not even
be aware of the growing competitiveness in the market, the pressure for
drug companies to keep the cost of drug development down, and the
pressure for service providers to deliver results in shorter timeframes
and at cheaper rates. Companies may not even be aware of the squeeze in
margins that is occurring. What they should be aware of is that only the
truly remarkable companies will survive, and those companies are
investing today in offering a unique and innovative service. They
recognise that true partnership comes from being there when the sponsor
crosses the finish line. Adding the right support in the second half of
the race is much more valuable than encouragement at the beginning – in
essence this is the left hand side of the value molecule.
Lean or Learning
If you want remarkable kids then you invest in their education; if you
want a remarkable business, your first investment should always be
education. The three pillars of education to invest in are:
Personnel Education
Interpersonal, customer facing and opportunity management skills are all
soft skills that should be pushed to the top of personal development
programmes across all job functions. These allow teams to work more
effectively; from a service provider point of view, they have more
client time than business development personnel do, and as a sponsor,
study personnel have better insight into what their requirements are
than procurement or fi nance, as they are on the front line.
With these skills ingrained, operational employees from both the sponsor
and the service provider are in a position where they are able to
interact with each other more effectively, understand exactly what their
needs might be, and suggest ideas where value can be added.
Product Education
I came from 20 years of selling items that go on a shelf. People buy
products they know, they understand and they see. Pepsi Max came out to a
certain sector of the market with a certain message attached to it and
there was no confusion about what it did. Consultancy services are the
same. They need to be boxed up. It needs to be a product so people can
say, “Yes, I want that. How do I interact with it? What does it look
like? What does it cost? What values can I deliver?” You need to educate
your business to do that.
Partner Education
Whatever part in the clinical development process you play, get
involved! Ask if you can have time to understand what is going on
outside your sphere of influence, to understand the different processes.
Ask for people’s opinions, and listen to what they have to say. Invest
some time to sit in on a meeting and get some expert experience.
Volunteer; make sure it is off the clock. Then contribute and be
valuable once you have been given the opportunity.
Conclusion
If you are not looking to formalise a strategic partnership, but want to
be considered as an innovative service provider or if you’re a sponsor
looking to leverage the investment made in the early stages of your
product development, the path to success is the same: go in search of
the gems within the CRO/sponsor relationship in order to develop a true
working partnership. |
Read full article from PDF >>
|
|
 |
|
| Rate this article |
You must be a member of the site to make a vote. |
|
Average rating: |
0 |
| | | | | |
|
|
 |
News and Press Releases |
 |
Janssen Announces Phase 1 Results for Bispecific Antibody Amivantamab in the Treatment of Patients with Advanced Non-Small Cell Lung Cancer Harbouring Exon 20 Insertion Mutations
BEERSE, BELGIUM, May 18, 2020 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced results from the Phase 1 CHRYSALIS study evaluating amivantamab (JNJ-6372) in the treatment of patients with advanced non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) Exon 20 insertion mutations.[i] Amivantamab is an EGFR and MET-targeted bispecific antibody, which targets activating and resistance EGFR mutations, and MET pathway activation.[ii],[iii] Investigators assessed efficacy using overall response rate (ORR) per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1), duration of response, as well as the safety profile of amivantamab,1 which were the basis of the U.S. Food and Drug Administration (FDA) Breakthrough Therapy Designation granted earlier this year.[iv]
More info >> |
|
 |
White Papers |
 |
|
Quality Systems Guide
Research Quality Association
This guide concentrates on the core, underlying principles of quality that are pivotal – explicitly or implicitly – to all quality management standards that impact on research and development.
More info >> |
|
 |
Industry Events |
 |
Evolution Summit
20-22 July 2020, The Ritz Carlton, Fort Lauderdale, FL
The 22nd Evolution Summit is the premium forum bringing leading drug
development executives and solution providers together. As an
invitation-only event, taking place behind closed doors, the Summit
offers an intimate environment for a focused discussion of key new
drivers shaping drug development.
More info >> |
|
|
